MOB2 and glioblastoma: Bioinformatic analyses of public databases combing our IHC data indicate that the mRNA and protein expression of MOB2 are downregulated in GBM patient samples and low expression of MOB2 correlates with poor prognosis of GBM patients, suggesting that MOB2 may function as a tumor suppressor and may has a prognostic value.